CJC-1295 (with DAC) prices

FROM PEPTIDES CALCULATOR

About CJC-1295 DAC

Source profile reviewed 2026-10-01 · Imported 2026-10-22. Read the full compound profile

CJC-1295 is a synthetic 30-residue analog of growth hormone-releasing hormone(1-29) developed by ConjuChem in Montreal: four substitutions (D-Ala2, Gln8, Ala15, Leu27) protect it from the enzyme DPP-IV, and a C-terminal lysine carries a maleimidopropionyl group, the Drug Affinity Complex, that bonds to cysteine 34 of serum albumin after injection and stretches the half-life from minutes to 5.8-8.1 days. In two phase 1 trials published in 2006, single and repeated subcutaneous doses of 20-250 mcg/kg in healthy adults raised growth hormone 2- to 10-fold for about 6 days and IGF-1 1.5- to 3-fold for 9-11 days while preserving GH pulses; a 2005-2006 phase 2 trial in HIV-associated visceral obesity was terminated and ConjuChem stopped development, so it was never approved anywhere. It is prohibited in sport under the WADA list, and a Norwegian doping laboratory found that a product sold as CJC-1295 was in fact the 29-residue amidated peptide without the DAC (usually called Mod GRF 1-29); the weekly milligram schedules that circulate online are extrapolations from the weight-based trial doses rather than tested regimens.

Formula

C165 H269 N47 O46

Molar mass

3,647.2 g/mol

CAS number

446262-90-4

Amino acids

30

Research evidence described in the source

Limitations noted in the source

• Individual claims and source links have not yet completed editorial verification.
• Evidence level, applicable study model, formulation, route and population remain unassigned.

Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.